Postibrutinib outcomes in patients with mantle cell lymphoma
Top Cited Papers
Open Access
- 24 March 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 127 (12), 1559-1563
- https://doi.org/10.1182/blood-2015-10-673145
Abstract
Key Points Patients with mantle cell lymphoma who progressed during treatment with ibrutinib have a poor outcome. There are no therapies that appear to be uniquely successful in the postibrutinib setting. The postibrutinib setting is an unmet need.Keywords
This publication has 11 references indexed in Scilit:
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsBlood, 2015
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood, 2015
- Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesAnnals of Oncology, 2015
- Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)Blood, 2014
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481SBTKMutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaCancer Discovery, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibThe New England Journal of Medicine, 2014
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphomaNature Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2013
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010